gsk2398852
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 13, 2013 (NCT01777243)
Timeline
Indications
Studied for
Mechanism of action
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk2398852
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03417830 | Phase 1 | Apr 6, 2018 | GlaxoSmithKline |
| NCT03044353 | Phase 2 | Jun 20, 2017 | GlaxoSmithKline |
| NCT01777243 | Phase 1 | May 13, 2013 | GlaxoSmithKline, IQVIA, University of London |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 2013 |
| IQVIA | For profit | 1 | 0 | 1 | 2013 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1